Form 8-K - Current report:
SEC Accession No. 0001171843-25-000112
Filing Date
2025-01-08
Accepted
2025-01-08 07:20:47
Documents
13
Period of Report
2025-01-08
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_010824.htm   iXBRL 8-K 21230
  Complete submission text file 0001171843-25-000112.txt   193850

Data Files

Seq Description Document Type Size
2 XBRL LABEL FILE bcrx-20250108_lab.xml EX-101.LAB 34240
3 XBRL PRESENTATION FILE bcrx-20250108_pre.xml EX-101.PRE 22375
4 XBRL SCHEMA FILE bcrx-20250108.xsd EX-101.SCH 3039
15 EXTRACTED XBRL INSTANCE DOCUMENT f8k_010824_htm.xml XML 3662
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 25516581
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)